IL10 and neoplasm: The efficacy of pembrolizumab in reducing the tumor burden was amplified by 4.5-fold thanks to IL-10 suppression, paving the way for further investigations on the potential role of IL-10 as a predictive biomarker of resistance as well as a druggable target [47].